Vertex Pharmaceuticals (VRTX) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Strategic direction and portfolio expansion

• Recent high-profile acquisitions, such as Crinetics, align with a strict R&D strategy focused on human causal biology, validated biomarkers, and specialty markets.

• Expansion into rare specialty endocrinology and renal disease areas, leveraging commercial expertise from cystic fibrosis (CF) to accelerate launches and global reach.

• Five key disease area pillars now include CF, hematology, acute pain, rare endocrine diseases, and renal, with upcoming launches and regulatory milestones.

• Key near-term catalysts include the PDUFA date for povetacicept in IgAN (Nov 30), phase II data for inaxaplin, and proof-of-concept data in myotonic dystrophy type 1 before year-end.

• Continued focus on commercial execution and integration of new assets to drive diversification and growth.

Commercial infrastructure and launch execution

• Commercial model has evolved from CF to include dedicated sales forces for hematology, acute pain, and rare endocrine diseases, with learnings applied across franchises.

• Field force for acute pain doubled in early 2026, supported by marketing initiatives and celebrity endorsements to drive awareness and access.

• Renal franchise aims for the largest field force and share of voice in novel disease-modifying therapies, leveraging nephrology expertise.

• Crinetics acquisition brings a specialty endocrine sales force, enhancing synergies and market reach.

• Management changes include a new EVP focused on the pain franchise to support complex launches and growth.

Clinical pipeline and regulatory milestones

• Povetacicept in IgAN remains on track for the November 30 PDUFA date, with strong differentiation in UPCR reduction, hematuria resolution, and patient-friendly administration.

• Expansion of povetacicept into additional renal and autoimmune indications, including primary membranous nephropathy and myasthenia gravis, with ongoing studies.

• Inaxaplin's AMPLIFIED phase II data expected before year-end, targeting a broader patient population and informing future regulatory strategy.

• Chronic pain franchise progressing with two phase III studies in diabetic peripheral neuropathy, aiming for data by mid-2027.

• Combination pain therapies (NaV1.7/NaV1.8) seen as synergistic, with future development contingent on ongoing study outcomes.